CRISPR Therapeutics AG (CRSP): Price and Financial Metrics


CRISPR Therapeutics AG (CRSP)

Today's Latest Price: $91.82 USD

4.53 (-4.70%)

Updated Oct 30 4:00pm

Add CRSP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CRSP Stock Summary

  • With a price/sales ratio of 87.99, CRISPR Therapeutics AG has a higher such ratio than 97.03% of stocks in our set.
  • Over the past twelve months, CRSP has reported earnings growth of 1,884.94%, putting it ahead of 99.08% of US stocks in our set.
  • Revenue growth over the past 12 months for CRISPR Therapeutics AG comes in at -63.63%, a number that bests just 2.63% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are ZYME, FATE, NKTR, ARVN, and CLLS.
  • CRSP's SEC filings can be seen here. And to visit CRISPR Therapeutics AG's official web site, go to www.crisprtx.com.

CRSP Stock Price Chart Interactive Chart >

Price chart for CRSP

CRSP Price/Volume Stats

Current price $91.82 52-week high $111.90
Prev. close $96.35 52-week low $32.30
Day low $90.01 Volume 1,056,100
Day high $96.68 Avg. volume 1,023,119
50-day MA $90.47 Dividend yield N/A
200-day MA $70.04 Market Cap 6.44B

CRISPR Therapeutics AG (CRSP) Company Bio


CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.


CRSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream


Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

CRISPR/Vertex' sickle cell gene therapy qualifies for accelerated review in Europe

The European Medicines Agency has granted Priority Medicines ((PRIME)) designation to CTX001, an autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease ((SCD)).CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics ([[CRSP]] -1.2%) and Vertex ([[VRTX]] -0.5%).PRIME status provides for enhanced development support and...

Seeking Alpha | September 22, 2020

CRISPR Therapeutics (CRSP) Investor Presentation - Slideshow

The following slide deck was published by CRISPR Therapeutics AG in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

CRISPR Therapeutics Stock Is a Strong Buy on the Dip

CRSP stock has pulled back 13% in the last two sessions on no news. The dip allows investors into a strong long-term story at a lower price.

InvestorPlace | September 9, 2020

CRISPR Therapeutics Stock Shows It Has Good Genes

CRISPR Therapeutics Stock Shows It Has Good Genes in Its Charts…CRSP

The Street RealMoney | August 18, 2020

Frontier Perspectives: CRISPR Therapeutics

Since its initial discovery as a genetic reprogramming tool in 2012, CRISPR has widely been regarded as a breakthrough scientific discovery and quickly become one of the hottest new biotechnologies…

Medium | August 6, 2020

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo 9.78%
3-mo 7.44%
6-mo 89.48%
1-year 82.29%
3-year 375.75%
5-year N/A
YTD 50.76%
2019 113.18%
2018 21.68%
2017 15.89%
2016 N/A
2015 N/A

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8243 seconds.